Vertex Pharmaceuticals Incorpor
Vertex Pharmaceuticals develops and commercializes therapies for cystic fibrosis (CF) and other diseases. Products include TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. The pipeline includes VX-522 for CF, VX-548 for pain, Exa-cel for sickle cell disease and beta thalassemia, and others. Inaxaplin treats APOL1-mediated glomerulosclerosis and hypertension. Vertex also develops treatments for Type 1 Diabetes, cancer, and Duchenne muscular dystrophy with various partners. The company sells products to specialty pharmacies and distributors in the US and abroad. Founded in 1989, Vertex is headquartered in Boston, Massachusetts.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): consistently high returns on capital, returns well above its cost of capital and high, stable gross margins (pricing power).
- Return on invested capital has stayed above 15% in 6 of the last 7 years (latest 17.5%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 17.5% against a cost of capital (WACC) of 6.0%, a spread of 11.5 percentage points.
- Pricing power: gross margin has held between 86% and 88% over the last 7 years (latest 86.2%).
- Consistent growth: revenue has compounded at 19.3% a year over 6 years, rising every year.
- Scale advantage: ranks #1 by enterprise value ($135 billion) among the 129 Biotechnology companies we cover.
Weaknesses
- Our discounted cash flow target price (278.89 USD) is 49% below the current price.
- Valued at a premium to its Biotechnology peers: P/E 34.9x vs. a median of 19.2x, P/FCF 43.1x vs. a median of 18.8x and EV/EBITDA 25.7x vs. a median of 15.0x.
- Unstable profitability: operating margin ranged from -2% to 48% over the last 7 years, with operating losses in 1 of them.
Key Financial Data